lubbock glp-1 medical weight loss clinics TX GLP-1 Weight Loss in Connecticut

The definitive impact of tirzepatide on cardiovascular disease will be addressed in the ongoing SURPASS-COVT study (ClinicalTrials.gov number, NCT04255433), which compares tirzepatide with dulaglutide in patients with T2DM and ASCVD

Common Injection Sites: Abdomen, Thighs, and Upper Arms The abdomen is the most used injection site, likely due to its ease of access, greater surface area, and usually less pain than other sites

For an accurate listing of ingredients in each product, please refer to your product packaging.

Its important for patients to understand that GLP-1 medications are not a skinny shot, but a tool designed to support metabolic health through long-term weight management

Limited in-person oversight - Telehealth consultations have inherent limitations